| Also known as |
GW0742, GW 0742 |
| Blood pressure |
Potential to lower blood pressure |
| Chemical name |
{4-[({2-[3-fluoro-4-(trifluoromethyl)phenyl]propan-2-yl}amino)thiazol-5-yl]methylsulfanylphenoxy}acetic acid |
| Dosage (medical) |
Not established for medical use |
| Dosage (sports) |
5-10 mg daily |
| Effects |
Increased endurance, enhanced fat burning, improved lipid profile |
| Formula |
C21H17F4NO3S2 |
| Half-life |
Approximately 24 hours |
| Hepatotoxicity |
Unknown, but potential risk due to lack of comprehensive studies |
| Lab Test |
Detection via specific drug tests for GW-0742 in anti-doping labs |
| Main action |
Activates PPARОґ receptors, enhancing energy metabolism and endurance |
| Side effects |
Potential long-term effects on cardiovascular health, unknown safety profile |
| Storage conditions |
Store at room temperature away from moisture and light |
| Substance class |
PPARОґ (Peroxisome Proliferator-Activated Receptor delta) agonist |
| Trade name |
Not commercially available under a specific trade name |
| Use in sports |
Used illicitly for enhancing athletic performance, particularly in endurance sports |
| Water Retention |
Minimal |
| Manufacturer |
Pharmaceutical |
